Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04781257
Other study ID # LMU-IMPH-AIDA-03
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date April 30, 2024

Study information

Verified date November 2023
Source Ludwig-Maximilians - University of Munich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The ERASE - TB study will be conducted in order to fill a critical unmet need for tuberculosis control. Persons who are in contact with an infectious TB case may become infected themselves. Among those who are infected, most will stay healthy but some will develop TB themselves. These people would benefit from preventive treatment, which would also stop TB from being spread to other persons. The problem currently is that it is impossible to determine with certainty who would require preventive treatment, and who will remain healthy. Out of 100 persons exposed to an infectious TB patient, only 2 will go on to have TB according to a study in Vietnam, but there are no good tests available to identify those with a risk for TB disease. Treating 100 persons to prevent 2 cases of TB is not effective, so preventive treatment is not used in adults and adolescents in Tanzania, Mozambique and Zimbabwe, where this study will be conducted, but also in many other settings. The ERASE - TB project will evaluate a number of newly developed diagnostic tests, to see which of those will be able to predict TB in persons at risk, and therefore steer preventive treatment well. For this, the investigators will invite 2,100 household contacts (HHC) of infectious TB patients, who are at least 10 years old, into the study. Everyone will be examined initially, and again in regular intervals, for 1.5 to 2 years; and whenever the participants will present with symptoms that could indicate that they develop TB. At every visit, the investigators will perform an X-ray and take some blood and urine samples to perform new candidate tests. At the first/baseline visit, all household contacts without TB will undergo a spirometry to evaluate their pulmonary function. If someone is unwell, the investigators will also examine sputum for the presence of TB bacilli. In the end, the investigators will then be able to say who of the persons in the study developed TB, and who remained healthy. From all samples taken at different timepoints, the investigators will then determine which test found TB early, and clearly distinguished between persons developing TB, and persons who would remain healthy .


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2100
Est. completion date April 30, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years and older
Eligibility Inclusion Criteria: TB index case: - Aged at least 18 years - Having at least one other person living in the household aged =10 years - Written informed consent to conduct socio-economic and clinical questionnaire, to provide a sputum sample for culture and sequencing, and to approach the household members. - Recently diagnosed with active pulmonary TB within the last 4 weeks - Has taken less than 7 daily doses of anti-TB treatment since diagnosis; ensuring a positive culture can still be obtained - Able to spontaneously produce sputum - Sputum microscopy positive in Ziehl-Neelsen or Auramine-O staining of ideally 2+ or higher, but at least 1+ on the IUATLD/WHO scale, OR (in case no sputum microscopy done) GeneXpert positive, at least TB "medium" - A firm home address, maintained unchanged for the last 6 months, that is accessible to visiting Household Contact: - Aged at least 10 years - Written informed consent for study participation, including HIV testing, and home visits by the study team for follow-up (for minors <18 yr.: consent of the parent/guardian, assent of the participant) - Recent (in the last 4 weeks), substantial exposure to an infectious TB case in the household, defined as sleeping at least 3/7 nights in the same household - If HIV negative: not on preventive therapy (preventive therapy is not an exclusion criterion for HIV positive persons) Exclusion Criteria: Household Contact - Circumstances that raise doubt on free, uncoerced informed consent (e.g. in a mentally handicapped person) - Prisoners - Recent treatment for active TB, completed within the last 30 days OR on current TB treatment for active TB.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
New test candidates
The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period: CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial

Locations

Country Name City State
Mozambique Instituto Nacional de Saúde (INS) Centro de Investigação e Treino em Saúde da Polana Caniço Maputo
Tanzania NIMR - Mbeya Medical Research Centre Mbeya
Zimbabwe Biomedical Research & Training Institute (BRTI) Harare

Sponsors (2)

Lead Sponsor Collaborator
Michael Hoelscher European and Developing Countries Clinical Trials Partnership (EDCTP)

Countries where clinical trial is conducted

Mozambique,  Tanzania,  Zimbabwe, 

References & Publications (3)

Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev. 2018 Jul 18;31(4):e00021-18. doi: 10.1128/CMR.00021-18. Print 2018 Oct. — View Citation

Fox GJ, Nhung NV, Sy DN, Hoa NLP, Anh LTN, Anh NT, Hoa NB, Dung NH, Buu TN, Loi NT, Nhung LT, Hung NV, Lieu PT, Cuong NK, Cuong PD, Bestrashniy J, Britton WJ, Marks GB. Household-Contact Investigation for Detection of Tuberculosis in Vietnam. N Engl J Med. 2018 Jan 18;378(3):221-229. doi: 10.1056/NEJMoa1700209. — View Citation

Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other To explore elements shaping adoption of new TB detection technologies among asymptomatic members of community (sub-study I) In-depth qualitative interviews will be conducted to understand how new technologies could support screening and follow-up of household contacts. August 2021 to February 2022
Primary Sensitivity and specificity of new diagnostics to diagnose co-prevalent TB against a clinica/microbiological reference standard case definition to determine sensitivity and specificity of new diagnostics for diagnosing TB earlier with a special focus on subclinical disease.
New diagnostics will be evaluated against a reference standard for classification of presence of, or development of TB disease in a person exposed to a source case; with the following possibilities:
Co--prevalent symptomatic TB
Co--prevalent subclinical TB
Minimal TB, with incident TB during follow-up
Remained healthy
Co-prevalent TB disease can be diagnosed at Baseline (Month 0)
Primary Evaluation of novel diagnostics for detection of developing, minimal TB against a clinica/microbiological reference standard case definition to evaluate novel diagnostics for detection of developing, minimal TB that would cause infectious disease in the future.
For reference standard case classification, see 1.
TB disease can be diagnosed through study completion, up to Month 24
Primary Enhancement of diagnostic performance by simulating testing algorithms coupled with a risk estimate from a mathematical model to enhance diagnostic performance by simulating testing algorithms coupled with a risk estimate from a mathematical model For reference standard case classification, see 1. TB disease can be diagnosed through study completion, up to Month 24
Secondary M.tb infection status as measured by an immunological assay M.tb infection status as measured by an immunological assay:
M.tb infected at baseline
M.tb uninfected at baseline through to end of study
Change of M.tb infection status from negative (baseline) to positive during follow-up
through study completion, up to Month 24
Secondary Classification of cases of co-prevalent or incident TB; through M.tb isolate sequencing and comparison with the source case isolate Classification of cases of co-prevalent or incident TB; through M.tb isolate sequencing and comparison with the source case isolate:
Secondary, infected by source case - defined timepoint of infection
Other, unknown source of infection - unknown timepoint of infection
through study completion, up to Month 24
Secondary Assessment of the proportion of HHC (without co-prevalent TB) with abnormal pulmonary function at baseline to assess the proportion of HHC (without co-prevalent TB) with abnormal pulmonary function at baseline, the type and severity of impairments, the relationship between pre-existing abnormal pulmonary function and incident TB (and the changes in pulmonary function measured by spirometry after incident TB and TB treatment completion). Spirometry will be done only at baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2